LVLiz Eliana Veramendi-Espinoza

Liz Eliana Veramendi-Espinoza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Liz Eliana Veramendi-Espinoza has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Toward a National Registry for Inborn Errors of Immunity in Peru: A Qualitative Implementation Study

    by Liz Eliana Veramendi-Espinoza, Kelly De la Cruz-Torralva, Armando Pezo-Pezo, Javier Vargas Herrera, Joan Neyra Quijandria, Martha Martina, Kathleen E. Sullivan, Moises A. Huaman, Jacqueline M. Knapke

    Background: Peru lacks an integrated information system for patients with Inborn Errors of Immunity (IEI). Although disease registries are essential tools for data management and health planning, their success depends on implementation science approaches that account for local contextual factors. This study reports Phase I of a three-phase mixed-methods implementation project to design and develop a national IEI registry. Methods: Phase I consisted of a phenomenological qualitative study exploring stakeholder perspectives. Semi-structured focus groups and in-depth interviews were conducted with 29 key stakeholders across four groups: policy-makers, clinical experts, end-users (immunologists, residents, allied health personnel), and patient organization representatives. Interviews followed a guide structured around four a priori domains (structure, navigation, feasibility, and perception of existing systems). Discussions were conducted in Spanish, audio-recorded, transcribed verbatim, and coded using ATLAS.ti. A hybrid thematic analysis combining deductive and inductive coding was performed. Data elements proposed for the registry were triangulated with qualitative findings. Results: Thirty-six initial codes were consolidated into 15 categories, which were further integrated into four overarching themes conceptualized as pathways toward intention to use: (1) Environment, where governance, regulatory backing, and sustainable financing were identified as key enablers, while limited interoperability emerged as a structural barrier; (2) Technical Dimension, emphasizing usability, alignment with clinical workflow, and a hierarchical data architecture (demographic–clinical–therapeutic); (3) Users, highlighting clinical leadership, protected time, digital readiness, and perceived usefulness as stronger motivators than financial incentives; and (4) Patients, underscoring data protection, transparency, trust, and advocacy as essential for legitimacy and sustainability. Conclusions: A national IEI registry in Peru is perceived as necessary and feasible if implemented with strong regulatory foundations, interoperable design, robust data security, and user-centered architecture. These findings informed the development of an initial functional prototype and the operational plan for Phase II, focused on usability evaluation.

  • Open Access

    Calidad de vida relacionada con la salud en niños peruanos con errores innatos de la inmunidad durante la pandemia de COVID-19: estudio transversal en dos hospitales de referencia de Lima, Perú

    by Liz Veramendi-Espinoza, Claudia Rentería-Valdiviezo, Andrés Hernández-Uribe, Javier Pérez-Rojas, Juan Carlos Aldave-Becerra

    Objetivo: Evaluar la calidad de vida relacionada con la salud (CVRS) en niños con errores innatos de la inmunidad (EII) atendidos durante la pandemia de COVID-19 en dos hospitales de referencia de Lima, Perú, y compararla con la de niños con sibilancias recurrentes o asma bronquial (SR/AB). Materiales y métodos: Estudio observacional transversal realizado entre junio y diciembre de 2021. Se invitó a los 63 pacientes de 2 a 17 años con EII registrados en los hospitales participantes; 50 completaron el estudio (tasa de respuesta: 79,4%). El grupo comparador estuvo conformado por 102 niños con SR/AB atendidos en los mismos hospitales y seleccionados a partir de listas de atención remota. La CVRS se evaluó con el Pediatric Quality of Life Inventory 4.0 (PedsQL 4.0) mediante las versiones de autorreporte y reporte de padres/cuidadores disponibles según edad. Los puntajes se compararon con la prueba U de Mann-Whitney y se realizaron análisis secundarios descriptivos según características clínicas seleccionadas. Resultados: Los pacientes con EII presentaron menores puntajes de CVRS que el grupo con SR/AB en el puntaje total y en los cuatro dominios, tanto según padres/cuidadores como según pacientes. En el reporte de cuidadores, la mediana del puntaje total fue 64,6 (RIC: 54,1-85,0) en EII y 94,5 (RIC: 85,0-98,4) en SR/AB (p<0,001). En el autorreporte, las medianas fueron 79,7 (RIC: 59,7-88,0) y 95,6 (RIC: 91,3-100), respectivamente (p<0,001). Las mayores diferencias se observaron en los dominios físico y escolar. Once pacientes con EII (22%) presentaron COVID-19: dos fueron asintomáticos, siete tuvieron cuadros leves y dos moderados. Conclusión: En esta cohorte atendida en dos hospitales de referencia durante la pandemia de COVID-19, los pacientes pediátricos con EII presentaron menor CVRS que el grupo comparador con SR/AB, especialmente en los dominios físico y escolar. La pandemia se interpreta como el contexto temporal del estudio; el diseño no permite atribuir causalmente las diferencias de CVRS a la pandemia o a la infección por SARS-CoV-2.

  • Open Access

    Implementing a National Registry of Patients with Inborn Errors of Immunity in Peru: A Mixed-Methods Protocol

    by Liz Veramendi-Espinoza, Kelly De la Cruz-Torralva, Joan Neyra Quijandria, Javier Vargas Herrera, Maritza Puray-Chávez, Percy Soto-Becerra, Leonardo Rojas-Mezarina, Moises A. Huaman, Jacqueline M. Knapke

    Background Inborn errors of immunity (IEIs) include more than 500 genetic disorders that cause recurrent infections, autoimmunity, and inflammatory complications. Although classified as rare diseases, their prevalence is increasing, making IEI an emerging public health problem. However, reliable national epidemiological data and coordinated follow-up data of IEI patients are lacking, which potentially affects up to 20,000 people in Peru. Objective In this study, we aim to describe the protocol of a three-phase mixed-method study that will design, build, and evaluate the usability and feasibility of the first Peruvian National IEI Registry. Methods Guided by the Exploration-Preparation-Implementation-Sustainment (EPIS) framework, Phase I (qualitative) will map stakeholder needs through in-depth interviews and focus groups; the data will undergo hybrid thematic analysis in ATLAS.ti. Phase II (pre-experimental) will enroll ≥20 clinical immunology consultants and residents to complete standardized tasks on the REDCap-based prototype; efficiency (task time), effectiveness (error rate), and satisfaction will be compared pre/post-iteration. Phase III (observational) will assess feasibility by enrolling ≥126 IEI cases across six national reference hospitals; the primary outcomes are clinical profile, data completeness, and accuracy. Results The study protocol received institutional review board approval in February 2025 from the UNMSM-Research Ethics Committee. Phase I enrollment started in March 2025. We expect our REDCap-based prototype to incorporate key needs and preferences gathered from focus groups and interviews to develop the platform. By the completion of the study phase II, we will have assessed the usability of the prototype platform. Study phase III will begin in April 2026. The final results are expected by November 2026 and will be published thereafter. Conclusions By evaluating usability and feasibility in real-world conditions, this protocol lays the groundwork for a national IEI registry. The resulting evidence will inform scale-up decisions and facilitate its incorporation into Peruvian health policy. Contributions to the literature - Shows how the EPIS framework can steer real-world adoption of a REDCap-based registry and prospectively measure usability and feasibility across six public hospitals involved in rare-disease surveillance. - Provides a mixed-methods protocol that designs, iterates and field-tests Peru’s first national registry for inborn errors of immunity, tackling persistent barriers to rare-disease data capture in low- and middle-income countries and offering a scalable blueprint for other resource-constrained settings. - Outlines a FAIR-aligned governance and data-sharing strategy that can be adapted by future programmes planning registries for rare and orphan diseases in similar contexts.


  • Open Access

    Clinical features, genotypes, and geographic distribution of 238 Latin American CGD patients

    by Tiago Santos de Oliveira, Ranieri Coelho Salgado, Lillian Nunes Gomes, Carolina Sanchez Aranda, Janáira Fernandes Severo Ferreira, Ekaterini Simões Goudouris, Fernanda Pinto Mariz, Maria Luiza Oliva Alonso, Solange Oliveira Rodrigues Valle, Luiz Fernando Bacarini Leite, et al.

    Chronic granulomatous disease (CGD) is an inborn error of immunity (IEI) caused by mutations in genes encoding components of the NADPH oxidase complex, leading to defective microbial killing and increased susceptibility to infections. This study analyzed clinical, genetic, and geospatial data from 238 CGD patients across eight Latin American countries. Genetic variants were identified in 141 patients (59%), with XL-CGD being the most common form (77%). Pneumonia (80%), lymphadenopathy (63%), and skin infections (55.5%) were frequent, with bacteria and fungi, such as Staphylococcus aureus, Aspergillus spp., and mycobacteria, as major pathogens. Antimicrobial prophylaxis was widely used, while IFN-γ was mainly prescribed in Mexico, mainly in cases of classic CGD (XL-CGD). Hematopoietic stem cell transplantation (HSCT) did not improve survival compared to prophylaxis. The leading cause of death was infection, particularly pneumonia and sepsis. XL-CGD patients had worse survival outcomes. The study highlights the need for improved genetic diagnosis, newborn screening, regional treatment guidelines, and expanded access to HSCT.


  • Open Access

    Anafilaxia inducida por el ejercicio dependiente del trigo: utilidad de la Gliadina Omega-5 en dos casos clínicos de Lima, Perú

    by Liz Veramendi-Espinoza, César Galván, Rafael Durán Galdo

    Antecedentes: La anafilaxia inducida por el ejercicio dependiente del trigo es una alteración excepcional, potencialmente mortal, desencadenada por el consumo de trigo después de realizar alguna actividad física. Reporte de caso: Se informan dos casos de pacientes adolescentes de Lima, Perú, diagnosticados con anafilaxia inducida por el ejercicio dependiente del trigo mediante pruebas de punción cutánea y el microarray Allergy Explorer 2 (ALEX-2), donde se identificó gliadina omega-5 (Tri a 19) como alérgeno principal. Aunque ambos pacientes tuvieron episodios de anafilaxia, solo uno requirió la administración de adrenalina. Conclusión: Es importante establecer el diagnóstico de anafilaxia inducida por el ejercicio dependiente del trigo mediante pruebas moleculares para confirmar la enfermedad y llevar a cabo estrategias preventivas (evitar el consumo de trigo antes de cualquier actividad física) y planes de emergencia. Los casos expuesto en este artículo subrayan la necesidad de tener mayor conciencia clínica y mejor acceso a intervenciones para salvar vidas en regiones con recursos y accesos limitados. Palabras clave: Anafilaxia; Hipersensibilidad al trigo; Alergias inducidas por actividad física; Perú; Gliadina omega-5; Alérgeno; Diagnóstico por métodos moleculares; Adrenalina.


  • Open Access

    Awareness of primary immunodeficiency diseases at a national pediatric reference center in Peru

    by Liz Eliana Veramendi-Espinoza, Jessica Hanae Zafra-Tanaka, Crhistian Toribio-Dionicio, Mariella R. Huamán, Gabriela Pérez, Wilmer Córdova-Calderón

    Objective To investigate the level of awareness of primary immunodeficiency diseases among physicians working at Instituto Nacional de Salud del Niño. Methods Cross-sectional study including pediatric residents and pediatricians working at the Instituto Nacional de Salud del Niño during the study period (2017-2019). Physicians working at the immunology unit and surgery departments were excluded. Three aspects of awareness of primary immunodeficiency diseases were investigated: education, general knowledge, and diagnostic suspicion and actions taken in the face of suspicion. Results [...] ABSTRACT Objective To investigate the level of awareness of primary immunodeficiency diseases among physicians working at Instituto Nacional de Salud del Niño. Methods Cross-sectional study including pediatric residents and pediatricians working at the Instituto Nacional de Salud del Niño during the study period (2017-2019). Physicians working at the immunology unit and surgery departments were excluded. Three aspects of awareness of primary immunodeficiency diseases were investigated: education, general knowledge, and diagnostic suspicion and actions taken in the face of suspicion. Results


  • Open Access

    Cow's milk allergy non‐responsive to amino acid‐based formula? A successful transplanted patient with immune dysregulation, polyendocrinopathy, enteropathy, and X‐linked syndrome

    by Liz Veramendi‐Espinoza, Claudia Alejandra Rentería‐Valdiviezo, Roxana Díaz‐Subauste, Juan Carlos Aldave‐Becerra, Guisela Alva‐Lozada, Marco Becilli, Franco Locatelli

    The wide variety of IPEX symptoms leads to diagnosis and treatment delay with fatal outcomes if left untreated before two first years of life. Cow's milk allergy non‐responsive to amino acid‐based formula must raise suspicion of this syndrome.

  • Open Access

    Cow's milk allergy non-responsive to amino acid-based formula? A successful transplanted patient with Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome

    by Liz Eliana Veramendi-Espinoza, Claudia Alejandra Rentería-Valdivi, Roxana Díaz-Subauste, Juan Carlos Aldave-Becerra, Guisela Alva Lozada, Marco Becilli, Franco Locatelli

    Cow's milk allergy non-responsive to amino acid-based formula must raise suspicion of Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome. This is a potentially fatal disease associated with food allergy, sometimes leading to diagnostic delay. In our case, early diagnosis and management provided life-saving therapy.

  • Open Access

    Factors associated with mortality in patients hospitalized with COVID-19: A prospective cohort in a Peruvian national referral hospital

    by Miguel A. Vences, Juan J Pareja-Ramos, Paula Otero, Liz E Veramendi-Espinoza, Melissa Vega-Villafana, Julissa Mogollón-Lavi, Eduardo Morales-Romero, Josseline Olivera-Vera, Carol Meza, Lucía J Salas-Lazo, et al.

    Objectives To describe and assess clinical characteristics and factors associated with mortality in adult patients with COVID-19 admitted to a national referral hospital in Peru. Methods We conducted a prospective cohort study that included hospitalized patients older than 18 years with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection diagnosis. Patients with a positive rapid serological test on admission but no respiratory symptoms nor compatible images were excluded. We collected the data from clinical records. Results A total of 813 adults were included, 544 (66.9%) with confirmed COVID-19. The mean age was 61.2 years (standard deviation: 15.0), and 575 (70.5%) were male. The most frequent comorbidities were hypertension (34.1%) and obesity (25.9%). On admission, the most frequent symptoms were dyspnea (82.2%) and cough (53.9%). A total of 114 (14.0%) patients received mechanical ventilation, 38 (4.7%) were admitted to the intensive care unit, and 377 (46.4%) died. The requirement for ventilatory support, greater lung involvement, and inflammatory markers were associated with higher mortality. It was found that for every 10-year age increase, the risk of dying increased 32% (relative risk: 1.32; 95% confidence interval: 1.25 to 1.38). Those who were admitted to the intensive care unit and were placed on mechanical ventilation had 1.39 (95% confidence interval: 1.13 to 1.69) and 1.97 (95% confidence interval: 1.69 to 2.29) times the risk of dying compared to those who did not, respectively. Conclusion We found a high mortality rate among hospitalized patients associated with older age, higher inflammatory markers, and greater lung involvement.


  • Diagnostic Delay of Primary Immunodeficiencies at a Tertiary Care Hospital in Peru- Brief Report

    by Liz E. Veramendi-Espinoza, Jessica H. Zafra-Tanaka, Gabriela A. Pérez-Casquino, Wilmer O. Córdova-Calderón

    The aim of the study was to assess the diagnostic delay in pediatric patients with primary immunodeficiencies (PID) at a tertiary care hospital in Peru.